This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Delving into the recent data published in JAMA Dermatology from the Phase 2 clinical trial of cendakimab in patients with atopic dermatitis
Ticker(s): BMYWho's the expert?
Institution: UC Irvine
- Immunodermatologist and Professor of Dermatology at University of California Irvine Medical Center.
- Treats 100 patients with Pemphigus, 100 patients with chronic itch, including 50 with Prurigo Nodularis, and 75 with alopecia areata.
- Leading expert and researcher on autoimmune related skin conditions; has published more than 225 papers/book chapters and awarded numerous research grants from NIH.
Interview Goalto discuss the current treatment landscape and the potential of cendakimab, an anti-IL-13 monoclonal antibody being developed by BMS for the treatment of atopic dermatitis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
